Paving the Way in Metabolic Diseases
We harness the power of oral enzymes with our novel oral biologic platform to address difficult-to-treat metabolic disorders and beyond.
Currently, there is no approved treatment for enteric hyperoxaluria, a disease marked by significantly elevated urine oxalate levels that can result in kidney stones and chronic kidney disease. Allena’s novel biologic platform has the potential to reduce oxalate levels and protect the kidneys from irreversible damage.
Hyperuricemia & Gout
Current treatments for hyperuricemia and gout have significant limitations, particularly for patients with reduced kidney function. Allena’s first-in-class non-absorbed urate-degrading enzyme has the potential to break down urate within the gastrointestinal (GI) tract, lowering the risk of complications associated with the condition.
Living with a metabolic disease such as hyperoxaluria or hyperuricemia
and gout can be painful and often frustrating. There may not be any therapeutic options for your condition, or if there are, they might not provide adequate relief. We believe you deserve better. That’s why we’re leveraging our extensive knowledge of oral enzymes to develop targeted therapies that may offer you relief.
Partner With Us
We are a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral enzyme therapies. If you are interested in exploring partnership opportunities and/or have a compelling technology that could complement our pipeline, we invite you to contact us by using the form below.
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346Read Press Release
Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment ConferenceRead Press Release